Design Therapeutics Past Earnings Performance
Past criteria checks 0/6
Design Therapeutics's earnings have been declining at an average annual rate of -49.6%, while the Biotechs industry saw earnings growing at 14.5% annually. Revenues have been declining at an average rate of 150.6% per year.
Key information
-49.6%
Earnings growth rate
-27.9%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | -150.6% |
Return on equity | -24.1% |
Net Margin | n/a |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Design Therapeutics (NASDAQ:DSGN) Is In A Good Position To Deliver On Growth Plans
Mar 15Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth
Nov 16Here's Why We're Not Too Worried About Design Therapeutics' (NASDAQ:DSGN) Cash Burn Situation
Jun 06Design Therapeutics (NASDAQ:DSGN) Is In A Good Position To Deliver On Growth Plans
Feb 09Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth
Oct 25Design Therapeutics GAAP EPS of -$0.27 misses by $0.02
Aug 08We're Not Very Worried About Design Therapeutics' (NASDAQ:DSGN) Cash Burn Rate
Jul 02Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth
Mar 18Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth
Dec 03Here's Why We're Not Too Worried About Design Therapeutics' (NASDAQ:DSGN) Cash Burn Situation
Aug 18Design Therapeutics expands board of directors
Jun 07Design Therapeutics EPS misses by $0.24
May 10Revenue & Expenses BreakdownBeta
How Design Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 0 | -67 | 21 | 0 |
30 Sep 23 | 0 | -72 | 22 | 0 |
30 Jun 23 | 0 | -74 | 21 | 0 |
31 Mar 23 | 0 | -69 | 20 | 0 |
31 Dec 22 | 0 | -63 | 19 | 0 |
30 Sep 22 | 0 | -57 | 18 | 0 |
30 Jun 22 | 0 | -51 | 16 | 0 |
31 Mar 22 | 0 | -43 | 14 | 0 |
31 Dec 21 | 0 | -36 | 11 | 0 |
30 Sep 21 | 0 | -28 | 8 | 0 |
30 Jun 21 | 0 | -19 | 6 | 0 |
31 Mar 21 | 0 | -13 | 4 | 0 |
31 Dec 20 | 0 | -8 | 2 | 0 |
31 Dec 19 | 1 | -2 | 1 | 0 |
Quality Earnings: DSGN is currently unprofitable.
Growing Profit Margin: DSGN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: DSGN is unprofitable, and losses have increased over the past 5 years at a rate of 49.6% per year.
Accelerating Growth: Unable to compare DSGN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: DSGN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: DSGN has a negative Return on Equity (-24.08%), as it is currently unprofitable.